IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

Suppiah, Vijayaprakash, Moldovan, Max, Ahlenstiel, Golo, Berg, Thomas, Weltman, Martin, Abate, Maria Lorena, Bassendine, Margaret, Spengler, Ulrich, Dore, Gregory J., Powell, Elizabeth, Riordan, Stephen, Sheridan, David, Smedile, Antonnia, Fragomeli, Vincenzo, Muller, Tobias, Bahlo, Melanie, Stewart, Graeme J., Booth, David R., George, Jacob and Hepatitis C Study (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41 10: 1100-1104. doi:10.1038/ng.447

Author Suppiah, Vijayaprakash
Moldovan, Max
Ahlenstiel, Golo
Berg, Thomas
Weltman, Martin
Abate, Maria Lorena
Bassendine, Margaret
Spengler, Ulrich
Dore, Gregory J.
Powell, Elizabeth
Riordan, Stephen
Sheridan, David
Smedile, Antonnia
Fragomeli, Vincenzo
Muller, Tobias
Bahlo, Melanie
Stewart, Graeme J.
Booth, David R.
George, Jacob
Hepatitis C Study
Title IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
Formatted title
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Journal name Nature Genetics   Check publisher's open access policy
ISSN 1061-4036
Publication date 2009-10
Sub-type Article (original research)
DOI 10.1038/ng.447
Volume 41
Issue 10
Start page 1100
End page 1104
Total pages 5
Place of publication New York, United States
Publisher Nature Genetics
Collection year 2010
Language eng
Subject 11 Medical and Health Sciences
1103 Clinical Sciences
Formatted abstract
Hepatitis C virus (HCV) infects 3% of the world’s population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN- α/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFNλ3; rs8099917 combined P = 9.25 × 10−9, OR = 1.98, 95% CI = 1.57–2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.  
Keyword Genome wide association
Gene expression
Antiviral activity
Virus replication
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2010 Higher Education Research Data Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1249 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1406 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 12 Nov 2009, 12:00:43 EST by Mr Andrew Martlew on behalf of School of Medicine